drugset / Trial / NCT04755920
SGM-101 in Colorectal Brain Metastases.
Phase 2
Unknown
10 enrolled
Leiden University Medical Center
Medical Center Haaglanden · collabSurgimab · collab
NaSingle-groupOpen-labelTreatment
Summary
This study assesses the feasibility of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody, for intraoperative near-infrared fluorescence imaging of colorectal brain metastases by injecting SGM-101 intravenously 3 - 5 days prior to surgery.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2026-02
- Completion
- 2026-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SGM-101 | Monoclonal antibody | 10 mg | Intravenous |